MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis

Haematologica

Volumn 100, Issue 11, 2015, Pages e471-e474

  Lazareth, Anne ^a,b,c   Song, Xiu Yi ^b,c   Coquin, Aurelie ^a   Harel, Stephanie ^d   Karlin, Lionel ^d   Belhadj, Karim ^e   Roos Weil, Damien ^f   Frenzel, Laurent ^g   Tamburini, Jerôme ^h   Macro, Margaret ⁱ   Chevret, Sylvie ^a   Loiseau, Hervé Avet ^j   Minvielle, Stephane ^k   Fermand, Jean Paul ^a,b,c   Soulier, Jean ^a   Bories, Jean Christophe ^b,c   Arnulf, Bertrand ^a,b,c  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITÉ PARIS DIDEROT   (France)

^d AVICENNE HOSPITAL   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

^h Institut Cochin   (France)

ⁱ Caen Hospital   (France)

^j CHU PURPAN   (France)

^k NANTES UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Heterogeneity; MB4 breakpoint; MMSET; Prognostic factor; t(414) translocation

Indexed keywords

BETA 2 MICROGLOBULIN; BORTEZOMIB; FIBROBLAST GROWTH FACTOR RECEPTOR 3; HISTONE METHYLTRANSFERASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; CHROMOSOME DELETION; COMPARATIVE STUDY; DEL(17P); FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TRANSLOCATION; GENOMIC INSTABILITY; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MULTIPLE MYELOMA SET DOMAIN; PANCREAS ISLET DISEASE; PHOSPHORYLATION; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; CHROMOSOME 14; CHROMOSOME 4; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL RATE;

ADULT; AGED; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 4; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; SURVIVAL RATE; TRANSLOCATION, GENETIC;

EID: 84946199787     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.127001     Document Type: Letter

References (15)

1. Avet-Loiseau H, Leleu X, Roussel M, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol. 2010;28(30):4630-4634.
2. Moreau P, Facon T, Leleu X, et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood. 2002;100(5):1579-1583.
3. Moreau P, Attal M, Garban F, et al. Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. Leukemia. 2007;21(9):2020-2024.
4. López-Corral L, Gutiérrez NC, Vidriales MB, et al. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells. Clin Cancer Res. 2011;17(7):1692-1700.
5. Karlin L, Soulier J, Chandesris O, et al. Clinical and biological features of t(4;14) multiple myeloma: a prospective study. Leuk Lymphoma. 2011;52(2):238-246.
6. Keats JJ, Reiman T, Maxwell CA, et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood. 2003;101(4):1520-1529.
7. Chesi M, Nardini E, Lim RS, et al. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood. 1998;92(9):3025-3034.
8. Marango J, Shimoyama M, Nishio H, et al. The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood. 2008;111(6):3145-3154.
9. Kuo AJ, Cheung P, Chen K, et al. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol Cell. 2011;44(4):609-620.
10. Pei H, Zhang L, Luo K, et al. MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature. 2011;470(7332):124-128.
11. Keats JJ, Maxwell CA, Taylor BJ, et al. Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients. Blood. 2005;105(10):4060-4069.
12. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1):3-9.
13. Chandesris MO, Soulier J, Labaume S, et al. Detection and follow-up of fibroblast growth factor receptor 3 expression on bone marrow and circulating plasma cells by flow cytometry in patients with t(4;14) multiple myeloma. Br J Haematol. 2007;136(4):609-614.
14. Jaffe JD, Wang Y, Chan HM, et al. Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. Nat Genet. 2013;45(11):1386-1391.
15. Oyer JA, Huang X, Zheng Y, et al. Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies. Leukemia. 2014;28(1):198-201.